Patents by Inventor Alex Melekhov

Alex Melekhov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20210369702
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 2, 2021
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. LIN, Thomas B. NEFF, Qingjian WANG, Volkmar GUENZLER-PUKALL, Lee A. FLIPPIN, Michael P. AREND, Alex MELEKHOV
  • METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE
    Publication number: 20170312268
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: February 3, 2017
    Publication date: November 2, 2017
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. Lin, Thamas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20150080425
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: July 16, 2014
    Publication date: March 19, 2015
    Applicant: FibroGen, Inc.
    Inventors: STEPHEN J. KLAUS, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • Stabilization of Hypoxia Inducible Factor (HIF) Alpha
    Publication number: 20130245037
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 19, 2013
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase
    Publication number: 20130203805
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 8, 2013
    Applicant: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Patent number: 8466172
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: June 18, 2013
    Assignee: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Publication number: 20110166145
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: December 2, 2010
    Publication date: July 7, 2011
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase
    Publication number: 20110166178
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: February 17, 2011
    Publication date: July 7, 2011
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thoams B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Publication number: 20060270699
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: July 28, 2006
    Publication date: November 30, 2006
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas Neff, Qingjian Wang, Michael Arend, Lee Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Publication number: 20060258702
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: July 28, 2006
    Publication date: November 16, 2006
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas Neff, Qingjian Wang, Michael Arend, Lee Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Publication number: 20060258660
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: July 28, 2006
    Publication date: November 16, 2006
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas Neff, Qingjian Wang, Michael Arend, Lee Flippin, Alex Melekhov
  • Methods of increasing endogenous erythropoietin (EPO)
    Publication number: 20060183695
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: April 17, 2006
    Publication date: August 17, 2006
    Applicant: FibroGen, Inc.
    Inventors: Stephen Klaus, Al Lin, Thomas Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael Arend, Lee Flippin, Alex Melekhov
  • Methods of increasing endogenous erythropoietin (EPO)
    Publication number: 20060178316
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: April 17, 2006
    Publication date: August 10, 2006
    Applicant: FibroGen, Inc.
    Inventors: Stephen Klaus, Al Lin, Thomas Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael Arend, Lee Flippin, Alex Melekhov
  • Methods of increasing endogenous erythropoietin (EPO)
    Publication number: 20060178317
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: April 17, 2006
    Publication date: August 10, 2006
    Applicant: FibroGen, Inc.
    Inventors: Stephen Klaus, Al Lin, Thomas Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael Arend, Lee Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Publication number: 20030176317
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: December 6, 2002
    Publication date: September 18, 2003
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Methods of increasing endogenous erythropoietin (EPO)
    Publication number: 20030153503
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: December 6, 2002
    Publication date: August 14, 2003
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov